Kymera Therapeutics presented new preclinical data for KT-579, an oral IRF5 degrader showing disease-modifying activity in lupus models, with effects comparable or superior to existing therapies. KT-579 targets multiple inflammatory pathways involved in lupus, including Type I interferons and pro-inflammatory cytokines. The ongoing Phase 1 trial in healthy volunteers aims to assess safety and IRF5 degradation, with data expected in the second half of 2026. Positive preclinical results support KT-579's potential as a novel oral treatment for lupus and other autoimmune diseases.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
